Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04434482 · ClinicalTrials.gov registry record · Phase 1

IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

A Phase 1 study of Small-cell Lung Cancer and Advanced Solid Tumours, sponsored by Impact Therapeutics.

Completed
Registry status
Phase 1
Development phase
59
Enrollment target
20
Study locations

NCT04434482 is a Phase 1 study of Small-cell Lung Cancer and Advanced Solid Tumours that has completed, run by Impact Therapeutics. The registered enrollment target is 59 participants, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04434482, a Phase 1 study of Small-cell Lung Cancer and Advanced Solid Tumours, has completed, sponsored by Impact Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
59 participants
Enrollment target
20
Study locations

Study Summary

This is an open-label, multi-center, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of PARP inhibitor IMP4297 and temozolomide combination therapy in patients with advanced solid tumors and with ES-SCLC who develops disease progression after 1L platinum-based regimen.

Conditions Studied

Small-cell Lung Cancer Advanced Solid Tumours

Interventions

  • DRUG IMP4297(senaparib)

Study Locations (20)

Other

  • Beijing Cancer Hospital - Beijing
  • Jilin Cancer Hospital - Jilin
  • Fudan University Shanghai Cancer Center - Shanghai
  • Hubei Cancer Hospital - Wuhan
  • Chungbuk National University Hospital - Cheongju-si
  • The Catholic university of Korea, st. Vincent's Hospital - Gyeonggi-do
  • Yonsei university health system, Severance Hospital - Seoul
  • Asan Medical Center - Seoul
  • China Medical University Hospital - Taichung
  • National Cheng Kung University Hospital - Tainan
  • Chi Mei Medical Center - Tainan
  • National Taiwan University Hospital - Taipei

New South Wales

  • Border Medical Oncology - Albury
  • Blacktown Hospital - Blacktown
  • Orange Hospital - Orange

Ohio

  • Gabrail Cancer Researh Center - Canton
  • Mark H. Zangmeister Center - Columbus

Illinois

  • GenHarp Clinical Solutions - Evergreen Park

Tennessee

  • Sarah Cannon Research Institute - Tennessee Oncology - Tennessee City

Victoria

  • Peninsula Health Frankston Hospital - Frankston

Trial Details

FieldValue
Enrollment Target 59 participants
Start Date 2020-08-07
Est. Completion 2024-04-29
Phase Phase 1

Sponsor

Impact Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04434482

The ClinicalTrials.gov registry entry for NCT04434482 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (74% lower). The listed sponsor is Impact Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which IMP4297(senaparib) is the first listed.

NCT04434482 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, New South Wales, Ohio.

Frequently Asked Questions

What is clinical trial NCT04434482 about?

NCT04434482 is a clinical study titled "IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer". This is an open-label, multi-center, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, PK characteristics and anti-tumor activity of PARP inhibitor IMP4297 and temozolomide combination therapy in patients with advanced solid tumors and with ES-SCLC who develops d...

What is the current status of trial NCT04434482?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2020-08-07. Estimated completion is 2024-04-29.

What conditions does trial NCT04434482 study?

This clinical trial studies the following conditions: Small-cell Lung Cancer, Advanced Solid Tumours.

What interventions are being tested in trial NCT04434482?

The interventions under investigation include: IMP4297(senaparib) (DRUG).

Who is sponsoring clinical trial NCT04434482?

This trial is sponsored by Impact Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04434482 being conducted?

This trial has 20 study locations across Illinois, Ohio, Tennessee, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Small-cell Lung Cancer

All registered trials for this condition

Advanced Solid Tumours

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.